• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Eli Lilly (LLY) Could Change Following Virginia Plant Groundbreaking

    Simply Wall St·10/23/2026 08:24:40
    Listen to the news
    • Eli Lilly broke ground on a new US$5b integrated manufacturing site near Richmond, Virginia, adding active ingredient and finished-medicine capacity for antibody drug conjugates and other complex therapies, while continuing to advance clinical data and partnerships across obesity, immunology and oncology.
    • The build out of U.S. production, paired with demand for Mounjaro and Zepbound and new delivery and ADC collaborations, tightens the link between Eli Lilly's research pipeline, manufacturing scale and its ability to meet cardiometabolic and specialty medicine demand.
    • We will now examine how Eli Lilly's US$5b Virginia manufacturing build out could influence its broader investment narrative for investors.

    Compare Eli Lilly's push into next generation obesity and oncology treatments with its peers by reviewing the hand picked 36 healthcare AI stocks shaping tomorrow's healthcare leaders.

    Eli Lilly Investment Narrative Recap

    Eli Lilly shareholders effectively back a simple thesis. The business needs to keep turning very strong demand for incretin drugs like Mounjaro and Zepbound into reliable supply, access and margins, while slowly broadening earnings into oncology, immunology and neuroscience. The new US$5b Virginia plant supports that belief by adding extra manufacturing depth to the story.

    In the near term, the main swing factor is whether incretin volume growth continues to outweigh U.S. pricing pressure and any legal or reimbursement setbacks. The biggest risk is that net price pressure on GLP 1 medicines accelerates or legal costs rise, which could offset the benefits of capacity expansion.

    The Metis TechBio lipid nanoparticle collaboration is the announcement that best fits alongside the Richmond build. Both move Eli Lilly further into complex modalities and targeted delivery that align with the planned antibody drug conjugate output in Virginia. Together, they indicate a pipeline that focuses heavily on sophisticated biologics rather than small molecule therapies.

    For you as an investor, that pairing matters for future catalysts and execution risk. The potential benefit is a wider set of high value drugs that can share manufacturing know how and potentially benefit from the expanded U.S. footprint. The trade off is higher scientific, regulatory and capital intensity at a time when the firm already carries a meaningful debt load and faces GLP 1 legal exposure.

    What Current Forecasts Assume For Eli Lilly

    Eli Lilly's narrative projects US$118.9b revenue and US$50.1b earnings by 2029. This rests on analysts modelling 14.3% yearly revenue growth and an earnings increase of about US$23.4b from US$26.7b today.

    Uncover why Eli Lilly's fair value indicates a valuation gap that is roughly aligned with its current price.

    NYSE:LLY 1-Year Stock Price Chart
    NYSE:LLY 1-Year Stock Price Chart

    Exploring Other Perspectives

    The most optimistic twist on Eli Lilly hinges on the Richmond ADC build being the missing piece for a bigger oncology story. Bullish analysts were already sketching earnings of US$56.3b on revenue of US$138.8b by 2029 before this project appeared. That is far above consensus, and those expectations could shift again as this facility progresses.

    Explore 11 other Eli Lilly fair value estimates, including one that suggests up to 31% upside from the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more investment ideas beyond Eli Lilly?

    If the Eli Lilly story has sharpened your thinking about healthcare and long term growth, it can help to widen the lens to other listed businesses that fit different risk and income profiles. The Simply Wall St Screener can help you quickly filter the market so you spend time only where the numbers match your preferences.

    • If you want potential growth with strict risk controls, focus on companies that score well on balance sheet strength by starting with a 30 resilient stocks with low risk scores tailored to more resilient profiles.
    • For investors who care about compounding quality at a reasonable entry point, use a valuation focused filter and review a 29 high quality undervalued stocks that blend stronger fundamentals with appealing pricing.
    • Income focused portfolios can target cash flow and payout together by scanning a 6 dividend fortresses designed for higher yielding businesses with robust dividend profiles.